Calif. drugmaker hopes to secure $80M from IPO

08/27/2014 | American City Business Journals

Calithera Biosciences, a California-based developer of cancer drugs led by CEO Susan Molineaux, aims to raise $80 million in an initial public offering. The company is working on a drug, CB-839, designed to block glutaminase, a nutrient that cancer cells consume for energy. Calithera plans to conduct trials to evaluate the drug's efficacy against breast cancer, acute lymphocytic leukemia, acute myeloid leukemia, multiple myeloma and non-Hodgkin lymphoma.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA